Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 Year follow-up study [7]

AIDS

Volumn 19, Issue 16, 2005, Pages 1934-1936

  Bongiovanni, Marco ^a   Bini, Teresa ^a   Capetti, Amedeo ^b   Trovati, Serena ^a   Di Biagio, Antonio ^c   Tordato, Federica ^a   Monferte, Antonella D'Arminio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LETTER; LIPIDOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 27544500144     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000189569.10471.b4     Document Type: Letter

References (8)

1. Palella FJ, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Hoggs RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Scheckter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.
3. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42:3218-3224.
4. Department of Health and Human Services. DHHS guidelines. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://aidsinfo.nih.gov. Accessed: 30 June 2005
5. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
6. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at week 48 of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type-1 infected protease inhibitor-experienced patients. J Infect Dis 2002; 185:599-607.
7. Hicks C, King MS, Gulick RM, Clinton-White A, Eron JJ, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18:775-779.
8. Bongiovanni M, Bini T, Tordato F, Cicconi P, Melzi S, Repetto D, et al. Immunovirological outcomes in 70 HIV-1 infected patients who switched to lopinavir/ritonavir after failing at least one protease-inhibitor-containing regimen: a retrospective cohort study. J Antimirob Chemother 2003; 51:171-174.